-
to the launch of the Bloomberg Cambridge University Corporate Bond Index later in 2025 and the delivery of the ongoing research programme related to the index project. The successful candidate will undertake desk
-
. The project will be jointly supervised by Dr Susanne Bornelöv (Biochemistry; https://www.sblab.uk ) and Dr Lukas Westlake (AstraZeneca), and the successful applicant will have the opportunity to work across
-
Integration for Experimentalists, which provides core training in electronics and hardware prototyping, commonly required in experimental research projects; Two experimental research projects (Mini and Midi
-
, enhanced sensors, anti-fouling protection and much more. Going beyond existing work using expensive fabrication of planar 2D metamaterials, this project explores routes to use nano-assembly to create 3D
-
non-clinical PhD studentship in cardiometabolic research, commencing October 2026 in the Department of Medicine (VPD Heart & Lung Research Institute), University of Cambridge. The project will be based
-
Supervisor: Professor Florian Markowetz Course start date: 1st Oct 2026 Overview Professor Florian Markowetz wishes to recruit a student to work on the project entitled: “Development and
-
Supervisor: Professor Richard Gilbertson and Dr Giulia Biffi For further information about the research group, please visit biffilab.wordpress.com . Project details Cancer-associated fibroblasts
-
Supervisors: Professor Sir Steve Jackson and Dr Mark O'Connor (AZ Partner) Course start date: 1st October 2026 Project details Targeted Alpha Therapy (TAT) selectively delivers high Linear Energy
-
dynamics of chromatin modifications required for transposon silencing. Project details This project aims to advance our understanding of small RNA-mediated chromatin silencing using advanced genomics and
-
Supervisors: Dr Tim Halim and Dr Gregory Hamm Course start: 1st October 2026 Overview The project will be supervised by Dr Tim Halim, Dr Albert Koulman (Institute of Metabolic Science) and Dr